News Sentiment

OGN sentiment intelligence

Organon & Co news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 63 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 13.52 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 63

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

-0.2% over one week, +0.6% over four weeks, trend active, and near fair-value range.

Latest direct headline Negative

Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -0.2% Price digesting
Trend fit Trend active 0.6% over four weeks
Fair value 0.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 25
Neutral 34
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 63
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 11
Business Wire 7
TradingView 6
Businesskorea 2
Seeking Alpha 2
MT Newswires 2
Stocktwits 1

Event Lens

What the news is about

Classified themes
Market update 40
Deals and strategy 13
Earnings 7
Balance sheet 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 63
Business Wire Direct company coverage

Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA

Organon and Samsung Bioepis have expanded their agreement to commercialize PYZCHIVA (ustekinumab), a biosimilar referencing STELARA, in Canada, bringing their collaboration to six biosimilars. PYZCHIVA is indicated for conditions like chronic plaque psoriasis, psoriatic arthritis

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 11:09
Source
Business Wire
KBR Direct company coverage

Samsung Bioepis, Organon expand Stelara biosimilar partnership to Canada

Samsung Bioepis and Organon have expanded their partnership, granting Organon commercialization rights in Canada for Pyzchiva, Samsung Bioepis' biosimilar of Stelara (ustekinumab). This addition brings their collaborative biosimilar portfolio in Canada to six products. The agreem

Tone
Positive 71/100
Event
Deals and strategy
Published
19 Jun 2026 10:40
Source
KBR
Businesskorea Direct company coverage

Samsung Bioepis and Organon Expand Agreement to Commercialize PYZCHIVA®, a Biosimilar Referencing STELARA® in Canada

Samsung Bioepis and Organon have expanded their commercialization agreement in Canada to include PYZCHIVA®, a biosimilar referencing STELARA® for various inflammatory conditions. This agreement deepens their collaboration to six biosimilars across immunology, oncology, and dermat

Tone
Positive 70/100
Event
Market update
Published
18 Jun 2026 22:39
Source
Businesskorea
Business Wire Direct company coverage

Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA®

Organon and Samsung Bioepis have expanded their development and commercialization agreement, granting Organon commercialization rights in Canada for PYZCHIVA®, Samsung Bioepis’s biosimilar referencing STELARA® (ustekinumab). This expands their Canadian biosimilar portfolio to six

Tone
Positive 73/100
Event
Market update
Published
18 Jun 2026 17:39
Source
Business Wire
Stock Titan Direct company coverage

Organon, Samsung Bioepis add sixth biosimilar for Canada

Organon and Samsung Bioepis have expanded their collaboration, granting Organon commercialization rights in Canada for PYZCHIVA®, Samsung Bioepis’s biosimilar referencing STELARA®. This addition brings their joint Canadian biosimilar portfolio to six products, covering immunology

Tone
Positive 74/100
Event
Market update
Published
18 Jun 2026 09:59
Source
Stock Titan
mykxlg.com Direct company coverage

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN)

Brodsky & Smith is investigating potential breaches of fiduciary duties by the Boards of Simulations Plus, Inc. (SLP), Roku, Inc. (ROKU), TruBridge, Inc. (TBRG), and Organon & Co. (OGN). These investigations concern whether the proposed acquisition prices for each company provide

Tone
Negative 39/100
Event
Deals and strategy
Published
16 Jun 2026 19:39
Source
mykxlg.com
Financier Worldwide Direct company coverage

Sun Pharma agrees $11.75bn acquisition of Organon

Sun Pharmaceutical Industries Limited is set to acquire US drugmaker Organon & Co for $11.75 billion in an all-cash transaction. This acquisition aims to strengthen Sun Pharma’s position in established brands, diversify its revenue streams, and expand its global footprint, partic

Tone
Positive 71/100
Event
Deals and strategy
Published
16 Jun 2026 14:39
Source
Financier Worldwide
Stock Titan Direct company coverage

Organon (OGN) director receives 17.8K phantom stock units as compensation

Organon & Co. director Cynthia M. Patton received 17,857.143 phantom stock units as compensation under the company's Non-Employee Director Savings Plan. These units, economically equivalent to common stock and valued at $13.44 each, will be settled in cash after her service concl

Tone
Neutral 50/100
Event
Balance sheet
Published
15 Jun 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

Organon (OGN) director Shalini Sharp receives 17,857 phantom stock units as cash-settled award

Organon & Co. director Shalini Sharp has received 17,857.143 phantom stock units as part of her routine compensation, granted under the company's Non-Employee Director Savings Plan. These units are economically equivalent to Organon common stock at $13.44 per unit and will be pai

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 20:42
Source
Stock Titan